TAL 8.1 may be used for HLA typing.
| Institute |
|---|
| Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151229 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | ELISA ; FACS ; IHC ; RIA ; WB |
| Target: | Human Leukocyte Antigens DR3, 6, 11, DRJ25 |
| Reactivity: | Human |
| Clone: | TAL 8.1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | TAL 8.1 may be used for HLA typing. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2b |
| Molecular weight: | 28 kDa |
| Immunogen: | Cells from the B line WVB coated with mouse antiserum followed by WVB class II antigen. |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | Human Leukocyte Antigens are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Bodmer J et al. 1984. Histocompatibility Testing. 432-8. ISBN-13: 978-0387134642 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.